Leadership Team

Emilio Cordova, PhD, MBA
Chief Executive Officer

Emilio joined the SAMDI Tech team from AIT Bioscience, where he was the Senior Vice President of Business Development. He has also held executive positions in sales, marketing, and business development at Worldwide Clinical Trials (WCT) and Bioanalytical Systems, Inc (BASi). He brings over 15 years experience in business development, marketing, and sales in contract research companies. Emilio has a PhD in Chemistry from University of Miami, postdoctoral experience at Harvard, and a MBA from Purdue University.

Michael D. Scholle, MS, MBA
Vice President of Operations and Technology

Michael manages business operations and technology at SAMDI Tech. He has over 15 years of molecular biology experience with expertise in protein engineering, biological and biochemical assays, and high-throughput robotics platforms. He has worked as a staff scientist at Integrated Genomics Inc, Argonne National Laboratory, and Amunix Inc. He has authored 16 peer-reviewed articles in both scientific and business journals. He has extensive experience in high-throughput screening and has co-developed SAMDI as a high-throughput, label-free platform technology. Michael has a MS in Biology from Northern Illinois University and a MBA from Roosevelt University-Chicago.

Zachary A. Gurard-Levin, PhD
Chief Scientific Officer

Zachary manages the scientific operations at SAMDI Tech. He has a multi-disciplinary expertise in chemistry, biology, and translational research with over 10 years of experience in the epigenetics and chromatin dynamics space. He has authored 17 peer-reviewed articles, received multiple research grants, and lead several drug discovery and diagnostics projects at the Institut Curie in Paris, France. Zack was also a pioneer SAMDI user and co-developed SAMDI as a high-throughput, label-free platform. Zack received his PhD in Chemistry from the University of Chicago and served a biochemistry postdoctoral fellowship at the Institut Curie.

Carmichael S. Roberts, PhD, MBA

Carmichael is a senior business advisor to SAMDI Tech Inc. He is also a partner at North Bridge Venture Partners. Prior to joining North Bridge, Carmichael co-founded and served as the President and CEO of Arsenal Biomedical, Inc., a medical device company. Carmichael co-founded and served as the President and CEO of Surface Logix, Inc., a drug optimization company. He was also co-founder Nano-Terra, Inc. and Diagnostics For All, Inc. Carmichael also worked in business development at GelTex, Inc., which was acquired by Genzyme for $1.3 billion. Prior to GelTex, he was responsible for new product and business development at Union Carbide. Carmichael received his Ph.D. in organic chemistry from Duke University and a postdoctoral fellowship at Harvard University. Carmichael also received his MBA from MIT Sloan.

Milan Mrksich, PhD

Milan is the Henry Wade Rogers Professor at Northwestern University with appointments in the Departments of Chemistry, Biomedical Engineering, and Cell Biology and he is the inventor of the SAMDI technology. His research combines synthetic chemistry with materials science to study important problems in cell biology. He develops biochips for a host of biological and biotechnological applications and develops mimics of the extracellular matrix for studies of cell adhesion and migration. He has patented several chip-based chemical technologies for rapidly screening biological molecules for active compounds. Five years ago, he founded, with Carmichael, Arsenal Medical Inc., a medical devices company that has a stent product in clinical trials. Technology Review magazine named him as a "100 Top Young Innovators" in 2002. He has 150 peer-reviewed publications, including 25 that are based on the SAMDI technology. Milan received his PhD from California Institute of Technology and served a postdoctoral fellowship at Harvard University.

Sandra Park, BS, MPP, JD
Legal Counsel

Sandra Park serves as Legal Counsel of SAMDI Tech, Inc. Sandra Park brings over 15 years of business experience in the life science industry and has built her career helping small and large companies define their strategy for product development through collaboration. Ms. Park's breadth of experience ranges from starting companies based on university technology to structuring multi-million dollar deals for financing and drug discovery collaborations. Just prior to serving as Legal Counsel, Sandra worked at Pfizer Pharmaceuticals. Before Pfizer, Ms. Park held numerous senior roles in companies including working in top-tier NY and Boston based law firms.

Ms. Park received a Bachelors of Arts from Cornell University, a Master of Public Policy from the Terry Sanford Institute of Public Policy at Duke University, and a Juris Doctorate from the Duke University School of Law.

Ms. Park also currently serves as pro bono legal counsel to Diagnostics For All, Inc., a non-profit organization dedicated to developing low-cost, low-tech diagnostics for the developing world.